Search

Displaying results 9981 - 9990 of 10000 in total
  1. Drug

    INCB3284

    go.drugbank.com/drugs/DB05130
    Experimental

    INCB3284 is a CCR2 antagonist for Inflammation-driven Diseases.

  2. Drug

    Praconase

    go.drugbank.com/drugs/DB05584
    Investigational

  3. Drug

    Clevudine

    go.drugbank.com/drugs/DB06683
    Investigational

  4. Drug

    KBP-COVID-19

    go.drugbank.com/drugs/DB15858
    Investigational

    Upon harvest, the antigens were purified, and these components underwent preclinical testing in animals. … As of July 2020, KBP is conducting a Phase 1/2 clinical trial to evaluate the safety and immunogenicity of KBP-COVID-19 vaccine in healthy patients (NCT04473690).

  5. Drug

    Ginkgolide A

    go.drugbank.com/drugs/DB06743
    ExperimentalNutraceutical

    Shows potential in a wide variety of inflammatory and immunological disorders.

  6. Drug

    BMS-564929

    go.drugbank.com/drugs/DB07286
    Experimental

    BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM).

  7. Drug

    Entolimod

    go.drugbank.com/drugs/DB12304
    Investigational

    Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer, Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among

  8. Drug

    ST-101

    go.drugbank.com/drugs/DB12621
    Investigational

    ST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer's Disease.[A260411]

  9. Drug

    Gestaclone

    go.drugbank.com/drugs/DB21090
    Experimental

    The usage of the INN stem '-clone' in the name indicates that Gestaclone is a hypnotic tranquillizer. Gestaclone has a monoisotopic molecular weight of 370.17 Da.

  10. Drug

    Cyclo(prolylglycyl)

    go.drugbank.com/drugs/DB04541
    Investigational

    NA-831 (Traneurocin), is under investigation in two clinical trials: NCT03538522 (completed, for mild cognitive impairment and Alzheimer’s disease) and NCT04452565 (unknown status, combination therapy